search
Back to results

Comparing a Synergistic Antimicrobial Cleanser and Gel to Normal Saline and an Amorphous Gel in Reducing Bioburden and Promoting Healing in Chronic Lower Extremity Ulcers

Primary Purpose

Wound of Skin

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Normal Saline and Amorphous gel
BIAKOS™ Antimicrobial Skin & Wound Cleanser, BIAKŌS Antimicrobial Wound Gel
Sponsored by
SerenaGroup, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Wound of Skin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. At least 18 years old
  2. Presence of a diabetic foot ulcer, Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the tendon or muscle provided it is below the medial aspect of the malleolus OR Presence of a full thickness venous leg ulcer (VLU)
  3. Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to the initial screening visit.
  4. Study ulcer size is a minimum of 0.75 cm2 and a maximum of 5 cm2 at first treatment visit for DFU OR a minimum of 2.0cm2 and a maximum of 20.0 cm2 at the first treatment visit for VLU.
  5. Adequate circulation to the affected extremity as demonstrated by a transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, OR an Ankle Brachial Index (ABI - measure of blood flow to the ankle) between 0.7 and ≤ 1.3 OR a toe brachial index >0.5 within 3 months of the first Screening Visit.
  6. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
  7. Subject understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
  8. Subject has read and signed the IRB approved Informed Consent Form before screening procedures are undertaken.

Exclusion Criteria:

  1. Study ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes or venous disease.
  2. A surgery for operative debridement or revascularization is planned for the ulcer to be treated.
  3. Index ulcer has a history of cancer or, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer.
  4. Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to first Screening Visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
  5. History of radiation at the ulcer site.
  6. Subject with DFUs who cannot adhere to strict offloading according to protocol standards in the opinion of the investigator.
  7. Subjects with VLUs who cannot adhere to multilayer compression.
  8. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment.
  9. Active treatment of infection anywhere in the body with IV antibiotics, at screening and baseline.
  10. Suspected or confirmed signs/symptoms of gangrene on any part of the affected limb.
  11. Known Osteomyelitis or bone infection of the affected foot or leg as verified by diagnostic imaging within 30 days prior to enrollment.
  12. Subject is pregnant or breast feeding.
  13. Study ulcer with a history of treatment with hyperbaric oxygen, growth factors or other biologic treatments, or a Cellular or Tissue-based Product (CTP) within 30 days of enrollment.
  14. Subject has a known or suspected allergy to products under study.
  15. Pregnancy or breast feeding.

Sites / Locations

  • The Serens Group Austin Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Normal saline wash and an amorphous gel (NSS-HG)

synergistic antimicrobial cleanser (AMC) and antimicrobial gel (AMG)

Arm Description

Normal Saline Wash and Amorphous Gel

Antimicrobial Skin & Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKOS™ BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel.

Outcomes

Primary Outcome Measures

Compare healing rates (percent area reduction) through digital device
Compare healing rates (percent area reduction) between normal saline wash and an amorphous gel (NSS-HG) to the combination of a synergistic antimicrobial cleanser (AMC) and antimicrobial gel (AMG) in chronic lower extremity ulcers.

Secondary Outcome Measures

Compare the reduction in bacterial bioburden
Compare the reduction in bacterial bioburden as determined by the MolecuLight Procedure (MiX) between lower extremity ulcers treated with NSS-HG and AMC-AMG as determined by the WoundChek Protease Status between lower extremity ulcers treated with NSS-HG and AMC-AMG.
Pain Score
The difference in pain scores between subjects treated with NSS-HG and AMC-AMG using the numeric PEG score. The PEG scale is a validated pain scoring system. It consists of three 1-10 rating scales.
Adverse Events
Compare the difference in adverse events between subjects treated with NSS-HG and AMC-AMG determined by adverse event reporting through case report forms.

Full Information

First Posted
October 27, 2021
Last Updated
April 25, 2023
Sponsor
SerenaGroup, Inc.
Collaborators
Sanara MedTech
search

1. Study Identification

Unique Protocol Identification Number
NCT05107050
Brief Title
Comparing a Synergistic Antimicrobial Cleanser and Gel to Normal Saline and an Amorphous Gel in Reducing Bioburden and Promoting Healing in Chronic Lower Extremity Ulcers
Official Title
A Randomized Double-blind Controlled Clinical Trial Comparing a Synergistic Antimicrobial Cleanser and Gel to Normal Saline and an Amorphous Gel in Reducing Bioburden and Promoting Healing in Chronic Lower Extremity Ulcers
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 1, 2021 (Actual)
Primary Completion Date
May 1, 2023 (Anticipated)
Study Completion Date
May 25, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SerenaGroup, Inc.
Collaborators
Sanara MedTech

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is a randomized double-blind controlled clinical trial designed to compare healing rates between normal saline wash in combination with an amorphous gel (NSS-HG) versus the grouping of a synergistic antimicrobial cleanser (AMC) and antimicrobial gel (AMG) in chronic lower extremity ulcers. After consenting, the ulcers of eligible subjects are measured, photographed and undergo the MolecuLight imaging procedure (MiX). The subject is then randomized to one of two arms: target ulcer cleansed saline wash and an amorphous gel (NSS-HG) or synergistic antimicrobial cleanser (AMC) and antimicrobial gel (AMG). After cleansing the wound a second MiX is performed. The subject is given a four-week supply.
Detailed Description
BIAKOS™ Antimicrobial Skin & Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKOS™ Antimicrobial Skin and Wound Cleanser is a pure, colorless, isotonic cleanser that is safe. The preservative, PHMB, at a concentration of 0.1% w/w is added to the product to inhibit the growth of microorganisms such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant Methicillin Resistant Staphylococcus aureus [MRSA). and fungus Candida albicans within the product. BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial PHMB. BIAKŌS Antimicrobial Wound Gel: • Resists microbial colonization within the gel during shelf storage. • Provides an amorphous gel covering. • Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wound of Skin

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized double-blind controlled clinical trial comparing a synergistic antimicrobial cleanser and gel to normal saline comparing to an amorphous gel in reducing bioburden and promoting healing in chronic lower extremity ulcers
Masking
ParticipantInvestigator
Masking Description
This protocol is double-blinded. Subjects will be randomized 1:1 to have their wound cleansed with either NSS-HG and AMC-AMG. Unblinded staff will prepare the solutions for the two arms the morning of the day of enrollment. NSS-HG and AMC-AMG will be placed in labeled containers consistent with the randomization scheme. Finally, the unblinded research staff will provide the subject with their 4-week supply of NSS-HG and AMC-AMG to take home. The unblinded staff will not assess the study ulcer.
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Normal saline wash and an amorphous gel (NSS-HG)
Arm Type
Active Comparator
Arm Description
Normal Saline Wash and Amorphous Gel
Arm Title
synergistic antimicrobial cleanser (AMC) and antimicrobial gel (AMG)
Arm Type
Experimental
Arm Description
Antimicrobial Skin & Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKOS™ BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel.
Intervention Type
Device
Intervention Name(s)
Normal Saline and Amorphous gel
Intervention Description
Saline - sodium chloride and water Amorphous hydrogel dressings are formulations of water, polymers
Intervention Type
Device
Intervention Name(s)
BIAKOS™ Antimicrobial Skin & Wound Cleanser, BIAKŌS Antimicrobial Wound Gel
Intervention Description
Antimicrobial Skin & Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial PHMB. BIAKŌS Antimicrobial Wound Gel: • Resists microbial colonization within the gel during shelf storage. • Provides an amorphous gel covering. • Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue.
Primary Outcome Measure Information:
Title
Compare healing rates (percent area reduction) through digital device
Description
Compare healing rates (percent area reduction) between normal saline wash and an amorphous gel (NSS-HG) to the combination of a synergistic antimicrobial cleanser (AMC) and antimicrobial gel (AMG) in chronic lower extremity ulcers.
Time Frame
4-weeks
Secondary Outcome Measure Information:
Title
Compare the reduction in bacterial bioburden
Description
Compare the reduction in bacterial bioburden as determined by the MolecuLight Procedure (MiX) between lower extremity ulcers treated with NSS-HG and AMC-AMG as determined by the WoundChek Protease Status between lower extremity ulcers treated with NSS-HG and AMC-AMG.
Time Frame
4-weeks
Title
Pain Score
Description
The difference in pain scores between subjects treated with NSS-HG and AMC-AMG using the numeric PEG score. The PEG scale is a validated pain scoring system. It consists of three 1-10 rating scales.
Time Frame
4-weeks
Title
Adverse Events
Description
Compare the difference in adverse events between subjects treated with NSS-HG and AMC-AMG determined by adverse event reporting through case report forms.
Time Frame
4-weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At least 18 years old Presence of a diabetic foot ulcer, Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the tendon or muscle provided it is below the medial aspect of the malleolus OR Presence of a full thickness venous leg ulcer (VLU) Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to the initial screening visit. Study ulcer size is a minimum of 0.75 cm2 and a maximum of 5 cm2 at first treatment visit for DFU OR a minimum of 2.0cm2 and a maximum of 20.0 cm2 at the first treatment visit for VLU. Adequate circulation to the affected extremity as demonstrated by a transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, OR an Ankle Brachial Index (ABI - measure of blood flow to the ankle) between 0.7 and ≤ 1.3 OR a toe brachial index >0.5 within 3 months of the first Screening Visit. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence). Subject understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen. Subject has read and signed the IRB approved Informed Consent Form before screening procedures are undertaken. Exclusion Criteria: Study ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes or venous disease. A surgery for operative debridement or revascularization is planned for the ulcer to be treated. Index ulcer has a history of cancer or, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer. Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to first Screening Visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study. History of radiation at the ulcer site. Subject with DFUs who cannot adhere to strict offloading according to protocol standards in the opinion of the investigator. Subjects with VLUs who cannot adhere to multilayer compression. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment. Active treatment of infection anywhere in the body with IV antibiotics, at screening and baseline. Suspected or confirmed signs/symptoms of gangrene on any part of the affected limb. Known Osteomyelitis or bone infection of the affected foot or leg as verified by diagnostic imaging within 30 days prior to enrollment. Subject is pregnant or breast feeding. Study ulcer with a history of treatment with hyperbaric oxygen, growth factors or other biologic treatments, or a Cellular or Tissue-based Product (CTP) within 30 days of enrollment. Subject has a known or suspected allergy to products under study. Pregnancy or breast feeding.
Facility Information:
Facility Name
The Serens Group Austin Research Center
City
Austin
State/Province
Texas
ZIP/Postal Code
78701
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparing a Synergistic Antimicrobial Cleanser and Gel to Normal Saline and an Amorphous Gel in Reducing Bioburden and Promoting Healing in Chronic Lower Extremity Ulcers

We'll reach out to this number within 24 hrs